Sign in
Taking people in United StatesPhase 2/3

Steroid added to pain injections during knee replacement surgery for knee osteoarthritis

Compares two steroid types added to pain injections in adults having knee replacement.

Key facts

Who runs it
Walter Reed National Military Medical Center
Where
Bethesda, United StatesSee the site
Trial code
Registry title
Use of Corticosteroid in Intraopertive Injections in Total Knee Replacement Surgery.
Status
Recruiting
Phase
Phase 2/3
People taking part
240 people, planned
Started
1 Sept 2026
Expected to end
31 Aug 2027
Type of study
Interventional, 3 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • PAI
  • PAI + steroid
  • PAI + zilretta
Record updated
19 August 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults having a first (primary) total knee replacement at certain US military health centers. It compares a standard pain injection given during surgery, with or without a steroid added.

Age
18 years or older
Sex
All sexes
Disease stage
People having a primary total knee replacement (TKA), for example for severe knee arthritis or injury. The surgery must be successful.

Main reasons for not taking part

  • Partial knee replacement (unicompartmental knee arthroplasty)
  • Repeat (revision) knee replacement
  • Women who are pregnant or breastfeeding
  • Allergy to ingredients of the pain injection, or a past bad reaction to the study steroids
  • People with diabetes cannot be in the methylprednisolone group

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • Patients within the MHS who are DEERS eligible undergoing primary TKA at Walter Reed National Military Medical Center (WRNMMC), Surgery Center of Chevy Chase or District Surgery Center
  • Age 18 or older
  • successful surgical intervention

Who cannot take part

  • Allergic to ingredients in PAI or previous adverse reaction to steroids being used in this study
  • Unicompartmental knee arthroplasty (UKA)
  • Revision total knee arthroplasty (rTKA)
  • Females who are pregnant or nursing
  • Diabetics will be excluded from Group 2 (standard PAI + methylprednisolone)

Where in United States

  • Walter Reed National Military Medical CenterBethesda, United StatesContact: John P Cody, MDTaking people

About the trial

What the trial wants to find out

The goal of this clinical trial is to find out which type of steroid medicine, when added to a standard pain-control injection during total knee replacement surgery, works best at reducing pain, limiting opioid use, and improving recovery in adults undergoing surgery for severe knee arthritis or injury.

Read full original descriptionShow less

The main questions it aims to answer are:

Does adding a steroid to the injection improve pain control and reduce opioid use after surgery? Is the newer extended-release steroid (Zilretta) more effective and safer-especially for patients with diabetes-than the traditional steroid (methylprednisolone)?

Researchers will compare:

Standard pain-control injection alone Standard injection plus methylprednisolone Standard injection plus Zilretta to see which option provides better pain relief, less opioid use, and improved knee function.

(Patients with diabetes or prediabetes will only be in the standard injection or Zilretta groups so researchers can study whether Zilretta is safer for blood sugar control.)

Participants will:

Be randomly assigned to one of the study groups during their total knee replacement surgery Receive the assigned pain-control injection around the knee joint

Be followed after surgery to measure:

Pain levels Opioid pain medication use Knee movement (range of motion) Whether another procedure (such as manipulation under anesthesia) is needed if the knee becomes too stiff Patient-reported outcome surveys about pain and function

The 3 groups in the trial

  • Standard PAIExisting treatment, for comparison

    Group1 (n=80; 40 non-diabetic and 40 diabetic participants): Standard PAI: 30 mg Toradol/ketorolac (30mg/ml), 49.25ml 0.5% ropivacaine (5mg/ml), and 0.5 mg epinephrine (1mg/ml), 0.8 ml clonidine (0.1mg/ml) and 8.45 ml 0.9% sodium chloride

    Treatment: PAI

  • MethylprednisoloneExisting treatment, for comparison

    2\. Group2 (n=40, non-diabetic): Standard PAI + 40mg methylprednisolone (n = 40)

    Treatment: PAI + steroid

  • ZilrettaExisting treatment, for comparison

    3\. Group3 (n=80; 40 non-diabetic and 40 diabetic participants): Standard PAI + 32mg Zilretta (triamcinolone acetonide extended release injectable suspension)

    Treatment: PAI + zilretta

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Adjunctive Use of Corticosteroid in Periarticular Injections in Primary Total Knee Arthroplasty
Plain-language title
Steroid added to pain injections during knee replacement surgery for knee osteoarthritisGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
19 August 2026